

## Supplemental Online Content

Shah SJ, Fine N, Garcia-Pavia P, et al. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: a post hoc analysis of the ATTR-ACT randomized clinical trial. *JAMA Cardiol*. Published online November 15, 2023. doi:10.1001/jamacardio.2023.4147

**eTable 1.** Change From Baseline to Month 30 in Echocardiographic Segmental Strain

Measures: Tafamidis, 80 mg, vs Placebo

**eTable 2.** Change From Baseline to Month 30 in Left Atrial Diameter: Tafamidis, 80 mg, vs Placebo

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Change From Baseline to Month 30 in Echocardiographic Segmental Strain Measures: Tafamidis, 80 mg, vs Placebo

Segmental Strain Measure	Treatment Group	Baseline		Change from Baseline, Month 30		Between-group LS mean difference (95% CI)	P value	Interpretation of between-group difference in change
		N	Mean (SD)	N	LS mean (SE)			
Basal septal longitudinal strain, %	Tafamidis 80 mg	173	-4.8 (2.9)	105	0.47 (0.26)	-0.03 (-0.68, 0.61)	.92	No difference
	Placebo	173	-4.9 (3.0)	81	0.50 (0.31)			
Mid septal longitudinal strain, %	Tafamidis 80 mg	173	-7.2 (3.9)	105	0.02 (0.34)	-1.84 (-2.79, -0.89)	<.001	Tafamidis prevented worsening
	Placebo	173	-7.5 (3.8)	81	1.86 (0.34)			
Apical septal longitudinal strain, %	Tafamidis 80 mg	173	-18.7 (7.7)	105	2.67 (0.60)	-1.52 (-3.51, 0.47)	.13	No difference
	Placebo	173	-19.3 (7.9)	81	4.20 (0.92)			
Basal lateral longitudinal strain, %	Tafamidis 80 mg	173	-7.1 (4.1)	105	0.61 (0.39)	-1.36 (-2.55, -0.16)	.03	Tafamidis prevented worsening
	Placebo	173	-7.3 (4.6)	81	1.97 (0.43)			
Mid lateral longitudinal strain, %	Tafamidis 80 mg	173	-8.6 (5.1)	105	0.01 (0.45)	-0.70 (-1.77, 0.37)	.20	No difference
	Placebo	173	-7.9 (4.5)	81	0.71 (0.42)			
Apical lateral longitudinal strain, %	Tafamidis 80 mg	173	-15.8 (7.0)	105	2.11 (0.47)	-0.23 (-2.32, 1.85)	.83	No difference
	Placebo	173	-16.3 (7.1)	81	2.35 (0.99)			
Basal circumferential strain, %	Tafamidis 80 mg	159	-11.7 (5.8)	94	-0.49 (0.77)	-1.95 (-4.14, 0.24)	.08	No difference
	Placebo	160	-12.4 (6.6)	69	1.46 (0.66)			
Mid circumferential strain, %	Tafamidis 80 mg	165	-16.9 (8.6)	101	-0.76 (0.82)	-2.92 (-4.77, -1.07)	.002	Tafamidis prevented worsening
	Placebo	172	-16.8 (9.6)	79	2.17 (0.65)			
Apical circumferential strain, %	Tafamidis 80 mg	157	-20.1 (10.2)	86	-2.28 (1.12)	-3.07 (-5.56, -0.59)	.02	Improved with tafamidis
	Placebo	156	-20.0 (10.6)	69	0.79 (1.14)			
Basal radial strain, %	Tafamidis 80 mg	157	10.2 (8.3)	92	1.62 (1.15)	0.96 (-1.96, 3.89)	.52	No difference
	Placebo	160	11.3 (7.7)	68	0.65 (1.55)			
Mid radial strain, %	Tafamidis 80 mg	165	18.7 (11.6)	101	-0.11 (1.02)	3.91 (0.97, 6.84)	.009	Tafamidis prevented worsening
	Placebo	171	17.6 (10.4)	79	-4.02 (1.13)			
Apical radial strain, %	Tafamidis 80 mg	157	18.0 (11.4)	83	1.78 (1.44)	4.27 (0.17, 8.38)	.04	Tafamidis prevented worsening
	Placebo	156	17.2 (12.0)	69	-2.50 (1.80)			

Abbreviations: CI, confidence interval; LS, least squares; SD, standard deviation; SE, standard error

**eTable 2.** Change From Baseline to Month 30 in Left Atrial Diameter: Tafamidis, 80 mg, vs Placebo

Left Atrial Diameter Measure	Treatment Group	Baseline		Change from Baseline, Month 30		Between-group LS mean difference (95% CI)	P value	Interpretation of between-group difference in change
		N	Mean (SD)	N	LS mean (SE)			
Left atrial anterior-posterior diameter, mm	Tafamidis 80 mg	169	43.9 (7.1)	102	-2.11 (0.59)	-1.13 (-3.06, 0.79)	.25	No difference
	Placebo	176	43.7 (6.1)	83	-0.98 (0.77)			
Left atrial medio-lateral diameter, mm	Tafamidis 80 mg	173	44.6 (6.4)	107	-1.68 (0.58)	0.04 (-1.54, 1.61)	.96	No difference
	Placebo	177	44.6 (6.2)	85	-1.72 (0.53)			
Left atrial superior-inferior diameter, mm	Tafamidis 80 mg	173	63.8 (7.7)	107	-1.59 (0.84)	-1.13 (-3.98, 1.71)	.43	No difference
	Placebo	177	64.2 (7.5)	85	-0.46 (1.21)			

Abbreviations: CI, confidence interval; LS, least squares; SD, standard deviation; SE, standard error